bioAffinity Technologies Q1 CyPath Lung Sales Exceed Projections, Up 146%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BIAF?
bioAffinity Technologies announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 146% growth compared to the first quarter of 2025, reflecting accelerating physician adoption and expanding clinical use of the Company's noninvasive lung cancer diagnostic test. "The stronger than expected unit growth in the first quarter of 2026 reflects growing recognition of the value that CyPath(R) Lung brings to clinical decision-making and patient outcomes," said Maria Zannes, President and CEO of bioAffinity Technologies. "Physicians are seeking more accurate, noninvasive tools to assess lung cancer risk and detect disease at its earliest, most treatable stage. CyPath(R) Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance. Our growing body of evidence - including real-world case studies - further supports CyPath(R) Lung's potential clinical utility."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIAF
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
bioAffinity Technologies' CyPath Lung Test Surpasses Sales Expectations
- Strong Sales Performance: bioAffinity Technologies reported a 146% year-over-year increase in unit sales of its CyPath Lung test in Q1 2026, exceeding market expectations and indicating robust demand for early lung cancer detection.
- Technological Innovation: The CyPath Lung test combines flow cytometry with AI to provide physicians with clear “likely” or “unlikely” malignancy results, significantly enhancing early diagnosis capabilities, particularly for Stage 1A lung cancer.
- Clinical Application Value: This test not only improves treatment outcomes but also reduces unnecessary invasive procedures when malignancy risk is low, thereby optimizing patient treatment experiences and healthcare resource utilization.
- Positive Market Reaction: Following the sales update, bioAffinity's stock rose over 8% in Wednesday's premarket trading, reflecting investor confidence in the company's future growth potential.
See More
Urban-Gro Merges with Flash Sports, Expands into Media Sector
- Merger Transition: Urban-Gro's merger with Flash Sports and Media signifies a successful shift from indoor agriculture to sports media, enhancing its growth potential in new markets, with a stock surge of 731% in March.
- Energy Market Gains: Turbo Energy benefited from rising energy prices due to tensions in the Middle East, reporting a $53 million backlog in industrial orders in March, showcasing its strong position in energy security, despite a 6% drop in premarket trading.
- Gas Asset Appreciation: AleAnna announced significant increases in proved reserves across key Po Valley fields amid global LNG supply shocks, enhancing the strategic importance of its Italian gas assets, with a stock increase of over 25% in March.
- Sales Growth and Outlook: bioAffinity's lung diagnostic product CyPath showed strong sales growth, with a projected 100% growth by 2026, indicating a successful transition to revenue-generating operations, leading to a 233% stock increase in March.
See More
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
BioAffinity Technologies Shares Surge 20% on Positive CyPath Lung Test Results
- Stock Surge: BioAffinity Technologies (BIAF) shares jumped approximately 20% in pre-market trading on Tuesday, reflecting strong market confidence in the company's future following a positive case study update.
- Successful Non-Invasive Test: The CyPath Lung test was administered to a 71-year-old former smoker, yielding a negative result for malignancy, which allowed the patient and physician to opt for a follow-up CT scan in three months, showcasing the test's effectiveness in assessing lung cancer risk.
- CT Scan Confirmation: Subsequent CT scans revealed that the suspicious lung nodules had resolved, confirming they were likely due to inflammation rather than cancer, thereby validating the accuracy and reliability of the CyPath Lung test.
- Significant Trading Volume: Over 4 million shares changed hands in pre-market trading, significantly surpassing the average of 300,000 shares, indicating heightened investor interest and engagement with BioAffinity.
See More
bioAffinity Technologies' CyPath Lung Test Surpasses Sales Expectations
- Strong Sales Performance: bioAffinity Technologies reported a 146% year-over-year increase in unit sales of its CyPath Lung test in Q1 2026, exceeding market expectations and indicating robust demand for early lung cancer detection.
- Technological Innovation: The CyPath Lung test combines flow cytometry with AI to provide physicians with clear “likely” or “unlikely” malignancy results, significantly enhancing early diagnosis capabilities, particularly for Stage 1A lung cancer.
- Clinical Application Value: This test not only improves treatment outcomes but also reduces unnecessary invasive procedures when malignancy risk is low, thereby optimizing patient treatment experiences and healthcare resource utilization.
- Positive Market Reaction: Following the sales update, bioAffinity's stock rose over 8% in Wednesday's premarket trading, reflecting investor confidence in the company's future growth potential.
See More
Urban-Gro Merges with Flash Sports, Expands into Media Sector
- Merger Transition: Urban-Gro's merger with Flash Sports and Media signifies a successful shift from indoor agriculture to sports media, enhancing its growth potential in new markets, with a stock surge of 731% in March.
- Energy Market Gains: Turbo Energy benefited from rising energy prices due to tensions in the Middle East, reporting a $53 million backlog in industrial orders in March, showcasing its strong position in energy security, despite a 6% drop in premarket trading.
- Gas Asset Appreciation: AleAnna announced significant increases in proved reserves across key Po Valley fields amid global LNG supply shocks, enhancing the strategic importance of its Italian gas assets, with a stock increase of over 25% in March.
- Sales Growth and Outlook: bioAffinity's lung diagnostic product CyPath showed strong sales growth, with a projected 100% growth by 2026, indicating a successful transition to revenue-generating operations, leading to a 233% stock increase in March.
See More
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
BioAffinity Technologies Shares Surge 20% on Positive CyPath Lung Test Results
- Stock Surge: BioAffinity Technologies (BIAF) shares jumped approximately 20% in pre-market trading on Tuesday, reflecting strong market confidence in the company's future following a positive case study update.
- Successful Non-Invasive Test: The CyPath Lung test was administered to a 71-year-old former smoker, yielding a negative result for malignancy, which allowed the patient and physician to opt for a follow-up CT scan in three months, showcasing the test's effectiveness in assessing lung cancer risk.
- CT Scan Confirmation: Subsequent CT scans revealed that the suspicious lung nodules had resolved, confirming they were likely due to inflammation rather than cancer, thereby validating the accuracy and reliability of the CyPath Lung test.
- Significant Trading Volume: Over 4 million shares changed hands in pre-market trading, significantly surpassing the average of 300,000 shares, indicating heightened investor interest and engagement with BioAffinity.
See More
